Voloridge Investment Management LLC Has $6.51 Million Stock Position in Twist Bioscience Co. (NASDAQ:TWST)

Voloridge Investment Management LLC decreased its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 55.3% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 139,991 shares of the company's stock after selling 172,977 shares during the period. Voloridge Investment Management LLC owned 0.23% of Twist Bioscience worth $6,505,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the business. Van ECK Associates Corp boosted its holdings in shares of Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after buying an additional 267 shares in the last quarter. Banque Transatlantique SA acquired a new stake in Twist Bioscience in the 4th quarter worth approximately $43,000. US Bancorp DE boosted its stake in Twist Bioscience by 72.0% in the 4th quarter. US Bancorp DE now owns 1,436 shares of the company's stock worth $67,000 after purchasing an additional 601 shares in the last quarter. KBC Group NV raised its position in Twist Bioscience by 71.4% during the 4th quarter. KBC Group NV now owns 2,942 shares of the company's stock worth $137,000 after buying an additional 1,226 shares during the last quarter. Finally, Teza Capital Management LLC purchased a new position in Twist Bioscience during the 4th quarter worth approximately $204,000.

Insider Activity at Twist Bioscience

In other news, SVP Paula Green sold 918 shares of the stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total value of $37,555.38. Following the completion of the transaction, the senior vice president now owns 130,912 shares of the company's stock, valued at approximately $5,355,609.92. This represents a 0.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Adam Laponis sold 936 shares of the firm's stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $29.75, for a total value of $27,846.00. Following the transaction, the chief financial officer now directly owns 106,018 shares of the company's stock, valued at $3,154,035.50. This represents a 0.88% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 26,850 shares of company stock valued at $974,764. Corporate insiders own 3.01% of the company's stock.

Twist Bioscience Trading Up 2.7%

Shares of NASDAQ:TWST traded up $0.79 during trading on Friday, reaching $29.68. 319,936 shares of the stock were exchanged, compared to its average volume of 977,738. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. Twist Bioscience Co. has a 12-month low of $27.12 and a 12-month high of $60.90. The firm has a market cap of $1.78 billion, a price-to-earnings ratio of -8.84 and a beta of 2.54. The firm's 50-day moving average price is $35.58 and its 200 day moving average price is $42.38.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.10). Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company had revenue of $92.79 million for the quarter, compared to analyst estimates of $92.00 million. On average, sell-side analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on TWST shares. JPMorgan Chase & Co. cut their target price on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. Robert W. Baird lowered their target price on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. The Goldman Sachs Group lowered their target price on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Guggenheim reissued a "buy" rating and set a $50.00 price target on shares of Twist Bioscience in a research report on Tuesday, May 6th. Finally, Barclays decreased their target price on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a research report on Thursday, April 10th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $50.40.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.